{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["135(4)"],"submitter":["Hong X"],"pubmed_abstract":["<h4>Backgrounds</h4>GALLIUM is a global phase III study that demonstrated significant improvements in progression-free survival (PFS) for obinutuzumab plus chemotherapy (G-chemo) vs. rituximab plus chemotherapy (R-chemo) in previously untreated patients with follicular lymphoma (FL). This study aimed to report the results of a subgroup of patients in China.<h4>Methods</h4>Patients were randomized to G-chemo or R-chemo. Responders received maintenance therapy for 2 years or until disease progression. The primary endpoint was investigator (INV)-assessed PFS. Secondary endpoints included the overall response rate (ORR) and complete response rate (CRR) at the end of induction chemotherapy, overall survival (OS), and safety.<h4>Results</h4>Overall, 58 patients with FL were randomized to the G-c"],"journal":["Chinese medical journal"],"pagination":["433-440"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8869628"],"repository":["biostudies-literature"],"pubmed_title":["Efficacy and safety of obinutuzumab for the first-line treatment of follicular lymphoma: a subgroup analysis of Chinese patients enrolled in the phase III GALLIUM study."],"pmcid":["PMC8869628"],"pubmed_authors":["Kinkolykh A","Li J","Hong X","Feng J","Lin T","Guo W","Wu G","Knapp A","Zhang Q","Song Y","Shi Y"],"additional_accession":[]},"is_claimable":false,"name":"Efficacy and safety of obinutuzumab for the first-line treatment of follicular lymphoma: a subgroup analysis of Chinese patients enrolled in the phase III GALLIUM study.","description":"<h4>Backgrounds</h4>GALLIUM is a global phase III study that demonstrated significant improvements in progression-free survival (PFS) for obinutuzumab plus chemotherapy (G-chemo) vs. rituximab plus chemotherapy (R-chemo) in previously untreated patients with follicular lymphoma (FL). This study aimed to report the results of a subgroup of patients in China.<h4>Methods</h4>Patients were randomized to G-chemo or R-chemo. Responders received maintenance therapy for 2 years or until disease progression. The primary endpoint was investigator (INV)-assessed PFS. Secondary endpoints included the overall response rate (ORR) and complete response rate (CRR) at the end of induction chemotherapy, overall survival (OS), and safety.<h4>Results</h4>Overall, 58 patients with FL were randomized to the G-c","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021 Sep","modification":"2026-06-01T02:29:15.203Z","creation":"2024-10-16T14:49:13.442Z"},"accession":"S-EPMC8869628","cross_references":{"pubmed":["35194005"],"doi":["10.1097/CM9.0000000000001737"]}}